Spectrum Pharma (SPPI) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. DOX
5. VRTX
6. CRWD
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to Spectrum Pharma (SPPI) Misses Q1 EPS by 1c

Spectrum Pharmaceuticals Reports First Quarter 2020 Financial Results and Pipeline Update

May 7, 2020 4:00 PM EDT

BLA for ROLONTIS® (eflapegrastim) under active FDA review - PDUFA date on October 24, 2020

ROLONTIS same day dosing study initiated

Updated Poziotinib strategy implemented to include new dosing regimens

Poziotinib ZENITH20 Cohort 3 fully enrolled

Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial... More